Evert Schimmelpennink

Evert Schimmelpennink

President and Chief Executive OfficeratLENZ Therapeutics· In proxies 2023–2025

Pay in FY2025+1% from the year before · LENZ Therapeutics stock -44.6% the same year

Evert Schimmelpennink was paid $7.0M in FY2025 (Dec), up 1%. LENZ Therapeutics stock fell 44.6% that year.

Pay$100 in the stock at the end of FY22 → $102
Pay is from the Summary Compensation Table of each LENZ Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. LENZ TherapeuticsPublic company · 3 yr
    • President and Chief Executive Officer2023 – Present · 3 yrStock in role -76%
  2. iBioPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  3. Contineum TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  4. Pipeline TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  5. iBio, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards2

  • iBioDirector · 4 yr on the boardIndependentCompensation—Paid as an executive
  • LENZ TherapeuticsDirector · 1 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?